Skip to main content

Advertisement

SpringerLink
Log in

Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis

  • Review Article
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Purpose

To assess the efficacy and safety of the novel sodium glucose co-transporter 2 (SGLT2) inhibitor—canagliflozin for type 2 diabetes (T2DM).

Methods

A search of Medline (1946–January 2014), Embase (1950–January 2014), and The Cochrane Library for randomized controlled trials of canagliflozin compared to placebo or active comparator in T2DM was performed. Clinical Trials website and unpublished U.S. Food and Drug Administration data were also searched.

Results

Ten trials including 6,701 patients were analyzed. Compared with placebo, canagliflozin produced absolute reductions in glycated hemoglobin A1c levels when used as monotherapy (weighted mean difference (WMD) −1.08 %, 95 % confidence interval (CI) [−1.25 to −0.90], p < 0.00001) or add-on treatment (WMD −0.73 %, 95 %CI [−0.84 to −0.61], p < 0.00001). When compared with other active comparators, canagliflozin significantly reduced HbA1c by −0.21 % (WMD, 95 %CI [−0.33 to −0.08], p = 0.001). Canagliflozin led to greater body weight loss (vs. placebo, WMD −2.81 kg, 95 %CI [−3.26 to −2.37]; vs. active comparators, WMD −3.49 kg, 95 %CI [−4.86 to −2.12]). Hypoglycemia with canagliflozin was similar to placebo or sitagliptin, and was lower than glimepiride (risk ratio (RR) 0.15, 95 %CI [0.10 to 0.22]). Genital tract infections were more common with canagliflozin (vs. placebo, RR 3.76, 95 %CI [2.23 to 6.35]; vs. active comparators, RR 4.95, 95 %CI [3.25 to 7.52]). Similar incidences of urinary tract infections were noted with canagliflozin compared with control groups.

Conclusion

Canagliflozin led to improvements in reducing glycated hemoglobin A1c levels and body weight with low risk of hypoglycemia in patients with T2DM. Common adverse effects including genital tract infections and osmotic diuresis-related AEs were identified and reviewed. Risks of cardiovascular events are even less certain, and more data on long-term effects are needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Danaei G, Finucane MM, Lu Y et al (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 378(9785):31–40

    Article  CAS  PubMed  Google Scholar 

  2. Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364–1379

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Tahrani AA, Bailey CJ, Del Prato S et al (2011) Management of type 2 diabetes: new and future developments in treatment. Lancet 378(9786):182–197

    Article  CAS  PubMed  Google Scholar 

  4. Cook MN, Girman CJ, Stein PP et al (2007) Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with type 2 diabetes in UK primary care. Diabet Med 24(4):350–358

    Article  CAS  PubMed  Google Scholar 

  5. Neumiller JJ, White JR Jr, Campbell RK (2010) Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs 70(4):377–385

    Article  CAS  PubMed  Google Scholar 

  6. Nair S, Wilding JP (2010) Sodium glucose co-transporter 2 inhibitors as a new treatment for diabetes mellitus. J Clin Endocrinol Metab 95(1):34–42

    Article  CAS  PubMed  Google Scholar 

  7. Rahmoune H, Thompson PW, Ward JM et al (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54(12):3427–3434

    Article  CAS  PubMed  Google Scholar 

  8. Gerich JE (2010) Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med 27(2):136–142

    Article  CAS  PubMed  Google Scholar 

  9. FDA advisory committee recommends approval of canagliflozin for treatment of adults with type 2 diabetes. 2013.Available from: http://www.fda.gov/ newsevents/newsroom/pressannouncements/ ucm345848. htm [Last accessed 28 October 2013]

  10. Lamos EM, Younk LM, Davis SN (2013) Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol 9(6):763–775

    Article  CAS  PubMed  Google Scholar 

  11. Riser Taylor S, Harris KB (2013) The clinical efficacy and safety of sodium glucose co-transporter 2 inhibitors in adults with type 2 diabetes mellitus. Pharmacotherapy 33(9):984–999

    Article  CAS  PubMed  Google Scholar 

  12. Musso G, Gambino R, Cassader M et al (2012) A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med 44(4):375–393

    Article  CAS  PubMed  Google Scholar 

  13. Clar C, Gill JA, Court R et al (2012) Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2(5). [PMC3488745]

  14. Vasilakou D, Karagiannis T, Athanasiadou E et al (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159(4):262–274

    Article  PubMed  Google Scholar 

  15. Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration

  16. Review Manager (RevMan) [Computer program] (2012) Version 5.2. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration

  17. Stenlof K, Cefalu WT, Kim KA et al (2013) Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 15(4):372–382

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Rosenstock J, Aggarwal N, Polidori D et al (2012) Dose-ranging effects of canagliflozin, a sodium-glucose co-transporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 35(6):1232–1238

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  19. Bode B, Stenlof K, Sullivan D et al (2013) Efficacy and safety of canagliflozin treatment in older patients with type 2 diabetes mellitus: a randomized trial. Hosp Pract 41(2):72–84

    Article  Google Scholar 

  20. Inagaki N, Kondo K, Iwasaki T et al (2013) Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study†. Diabetes Obes Metab 15(12):1136–1145

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Wilding JP, Charpentier G, Hollander P et al (2013) Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial. Int J Clin Pract 67(12):1267–1282

    Article  CAS  PubMed  Google Scholar 

  22. Janssen Research & Development LLC. The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone). (NCT01106690). ClinicalTrials.gov Web site. [Last accessed 28 October 2013]

  23. Yale JF, Bakris G, Cariou B et al (2013) Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 15(5):463–473

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  24. Lavalle-González FJ, Januszewicz A, Davidson J et al (2013) Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 56(12):2582–2592

    Article  PubMed Central  PubMed  Google Scholar 

  25. Schernthaner G, Gross JL, Rosenstock J et al (2013) Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care 36(9):2508–2515

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  26. Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 weeks results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382(9896):941–950

    Article  CAS  PubMed  Google Scholar 

  27. American Diabetes Association (2013) Standard of medical care in diabetes—2013. Diabetes Care 36(suppl 1):S11–S66

    Article  PubMed Central  Google Scholar 

  28. Fowler MJ (2007) Diabetes treatment, part 2: oral agents for glycemic management. Clin Diabetes 25:131–134

    Article  Google Scholar 

  29. Guh DP, Zhang W, Bansback N et al (2009) The incidence of comorbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 9:88

    Article  PubMed Central  PubMed  Google Scholar 

  30. Sha S, Devineni D, Ghosh A et al (2011) Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glu-cose excretion and increases urinary glu-cose excretion in healthy subjects. Diabetes Obes Metab 13:669–672

    Article  CAS  PubMed  Google Scholar 

  31. Kahleova H, Mari A, Nofrate V et al (2012) Improvement in β-cell function after diet-induced weight loss is associated with decrease in pancreatic polypeptide in subjects with type 2 diabetes. J Diabetes Complicat 26(5):442–449

    Article  CAS  PubMed  Google Scholar 

  32. Calado J (2009) Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. IDrugs 12(12):785–798

    CAS  PubMed  Google Scholar 

  33. Weidmann P, De Court M, Ferrari P (1992) Effect of diuretics on the plasma lipid profile. Eur Heart J 13(suppl G):61–67

    Article  PubMed  Google Scholar 

  34. Devineni D, Morrow L, Hompesch M et al (2012) Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab 14(6):539–545

    Article  CAS  PubMed  Google Scholar 

  35. Davis SN, Shavers C, Mosqueda-Garcia R, Costa F (1997) Effects of differing antecedent hypoglycemia on subsequent counter-regulation in normal humans. Diabetes 46:1328–1335

    Article  CAS  PubMed  Google Scholar 

  36. U.S. Food and Drug Administration. FDA Briefing Document. NDA204042. Invokana (Canagliflozin) Tablets. Rockville, MD: U.S. Food and Drug Administration; 2013. Accessed at www.fda.gov/downloads/Advisory Committees/ Committees Meeting Materials/Drugs/Endo-crinologic and Metabolic Drugs Advisory Committee /UCM334550.pdf on 24 January 2013

  37. Cardiovascular disease risk factors. World Heart Federation 2014; http:// www.world-heart-federation.org/cardiovascular-health/cardiovascular-disease- risk- factors/ (Last accessed on 12 January 2014)

  38. Janssen Research & Development, LLC. A Randomized, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of JNJ-28431754 on Cardiovascular Outcomes in Adult Subjects With Type 2 Diabetes Mellitus ClinicalTrials.gov Web site. (Last accessed on 12 January 2014)

Download references

Conflict of interest

The authors have nothing to disclose

Author information

Authors and Affiliations

  1. Department of Pharmacy, The TCM Hospital Affiliated to Luzhou Medical College, Luzhou, 646000, Sichuan Province, People’s Republic of China

    Xu-Ping Yang & Hong-Ping Shen

  2. Department of ENT, The Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, People’s Republic of China

    Dan Lai

  3. Department of Pharmacy, The Affiliated Hospital of Luzhou Medical College, Luzhou, 646000, Sichuan Province, People’s Republic of China

    Yi-Lan Huang

  4. College of Pharmacy, Luzhou Medical College, Luzhou, 646000, Sichuan Province, People’s Republic of China

    Xiao-Yan Zhong

Authors
  1. Xu-Ping Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dan Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Yan Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong-Ping Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yi-Lan Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yi-Lan Huang.

Additional information

Xuping Yang and Dan Lai are co-authors

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(DOC 36 kb)

ESM 2

(DOC 50 kb)

ESM 3

(DOC 55 kb)

ESM 4

(DOC 41 kb)

ESM 5

(DOC 41 kb)

ESM 6

(DOC 40 kb)

ESM 7

(DOC 40 kb)

ESM 8

(DOC 40 kb)

ESM 9

(DOC 40 kb)

ESM 10

(DOC 40 kb)

ESM 11

(DOC 39 kb)

ESM 12

(DOC 39 kb)

ESM 13

(DOC 38 kb)

ESM 14

(DOC 40 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yang, XP., Lai, D., Zhong, XY. et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis. Eur J Clin Pharmacol 70, 1149–1158 (2014). https://doi.org/10.1007/s00228-014-1730-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-014-1730-x

Keywords

Search

Navigation